Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
2,995
Views
5
CrossRef citations to date
0
Altmetric
Haematology

Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

Ali McBridea The University of Arizona Cancer Center, Tucson, AZ, USA;b Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ, USA;c Banner University Medical Center, Tucson, AZ, USAORCID Iconhttps://orcid.org/0000-0002-9430-4675
ORCID Icon,
Karen MacDonaldd Matrix45, Tucson, AZ, USAORCID Iconhttps://orcid.org/0000-0002-4568-9783
ORCID Icon,
Adolfo Fuentes-Alburoe Viatris Inc, Canonsburg, PA, USAORCID Iconhttps://orcid.org/0000-0003-0564-2507
ORCID Icon &
Ivo Abrahama The University of Arizona Cancer Center, Tucson, AZ, USA;b Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ, USA;d Matrix45, Tucson, AZ, USA;f Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0490-4421
ORCID Icon
Pages 598-606 | Received 29 Jan 2021, Accepted 08 Apr 2021, Published online: 10 May 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Consuela Cheriece Yousef, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem & Ivo Abraham. (2023) Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. Journal of Medical Economics 26:1, pages 394-402.
Read now

Articles from other publishers (4)

Sherin Ismail, Laila Abu Esba, Mansoor Khan, Hana Al-Abdulkarim, Hind Modimagh & Consuela Yousef. (2022) An Institutional Guide for Formulary Decisions of Biosimilars. Hospital Pharmacy 58:1, pages 38-48.
Crossref
Ching-Yu WangHaesuk ParkCoy D HeldermonScott M VouriJoshua D Brown. (2022) Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population. Journal of Managed Care & Specialty Pharmacy 28:7, pages 795-802.
Crossref
Ali McBride, Neda Alrawashdh, Karen MacDonald & Ivo Abraham. (2022) Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology 18:3, pages 363-373.
Crossref
Karen MacDonald, Neda Alrawashdh, Ali McBride & Ivo Abraham. (2021) Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 17:33, pages 4561-4570.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.